Leadership Overview
Cadila Pharmaceuticals has 10 executives leading key functions including finance, operations, revenue, regulatory affairs, and human resources.
Driven by a commitment to innovation, Cadila Pharmaceuticals operates across the full spectrum of pharmaceutical manufacturing, from APIs and finished formulations to biotechnology products, underscoring a dedication to global health and accessible medicine.
Driven by a commitment to innovation, Cadila Pharmaceuticals operates across the full spectrum of pharmaceutical manufacturing, from APIs and finished formulations to biotechnology products, underscoring a dedication to global health and accessible medicine.
Leadership Roles at Cadila Pharmaceuticals
Sandeep Rathi - Chief Financial Officer
Sandeep Rathi, the Chief Financial Officer at Cadila Pharmaceuticals, directs all financial operations and strategic fiscal planning. Rathi oversees budgeting, forecasting, and financial reporting, ensuring robust fiscal health across the organization. This leadership role involves managing capital allocation, optimizing financial performance, and driving profitability in alignment with Cadila Pharmaceuticals' integrated manufacturing model. By implementing stringent financial controls and exploring new investment avenues, Sandeep Rathi strengthens the company's market position and supports its expansion into diverse product categories, including APIs, finished formulations, and biotechnology products. The Chief Financial Officer's strategic insights are crucial for navigating market dynamics and sustaining long-term financial stability for the company's extensive operations.
Kamalesh Kalidasan - Chief Operating Officer
Kamalesh Kalidasan, the Chief Operating Officer at Cadila Pharmaceuticals, orchestrates the company's extensive manufacturing and operational activities. Kalidasan directs the seamless execution of production processes across all integrated business units, from API and intermediate manufacturing to finished formulations and biotechnology products. This critical role ensures operational efficiency, quality control, and supply chain optimization throughout the entire product lifecycle. By driving process improvements and resource management, Kamalesh Kalidasan supports Cadila Pharmaceuticals' commitment to delivering high-quality pharmaceutical machinery and OTC food supplements. The Chief Operating Officer's focus on operational excellence is fundamental to maintaining the company's competitive edge and expanding its global reach within the pharmaceutical sector.
Mitul Dave - Chief Operating Officer- CSBU
Mitul Dave, the Chief Operating Officer- CSBU at Cadila Pharmaceuticals, manages critical operational functions within the company's core strategic business units. Dave oversees the day-to-day operations, ensuring efficient production and delivery of a diverse range of products, including APIs, intermediates, finished formulations, and OTC food supplements. This role focuses on optimizing internal processes, enhancing productivity, and maintaining the highest standards of quality across all CSBU activities. By driving operational improvements and resource allocation, Mitul Dave contributes significantly to Cadila Pharmaceuticals' ability to meet market demands and expand its product offerings. The Chief Operating Officer's dedication to operational excellence within the CSBU is integral to the company's overall success and its mission to provide accessible healthcare solutions.
Wilton Franca - President - Latam
Wilton Franca, the President - Latam at Cadila Pharmaceuticals, directs the company's strategic operations and market development across the Latin American region. Franca oversees all commercial activities, sales, and distribution networks within Latam, ensuring alignment with Cadila Pharmaceuticals' global objectives. This leadership role involves navigating regional market dynamics, fostering key relationships with local stakeholders, and driving revenue growth for the company's comprehensive product portfolio, which includes APIs, finished formulations, and biotechnology products. By implementing tailored strategies for the Latin American market, Wilton Franca expands Cadila Pharmaceuticals' footprint and enhances its accessibility in this vital economic zone. The President's focus on regional expansion is crucial for achieving sustained international growth.
Sanjay Shrivastava - Global President, Regulatory Affairs
Sanjay Shrivastava, the Global President, Regulatory Affairs at Cadila Pharmaceuticals, leads the company's comprehensive regulatory compliance and strategy worldwide. Shrivastava ensures adherence to all international and national regulatory standards governing the manufacturing and distribution of pharmaceuticals, including APIs, finished formulations, and biotechnology products. This pivotal role involves managing submissions, approvals, and post-market surveillance to facilitate market access and maintain product integrity. By expertly navigating complex regulatory landscapes, Sanjay Shrivastava safeguards Cadila Pharmaceuticals' reputation and supports its global expansion efforts. The Global President's expertise in regulatory affairs is indispensable for ensuring product safety, efficacy, and compliance across all operational territories.
Suresh Balasubramanian - President - Plantations
Suresh Balasubramanian, the President - Plantations at Cadila Pharmaceuticals, oversees the strategic management and operational efficiency of the company's plantation assets. Balasubramanian directs all aspects of plantation cultivation, resource management, and yield optimization, ensuring sustainable practices and maximum output. This role is integral to supporting Cadila Pharmaceuticals' broader business objectives, potentially by providing raw materials or contributing to the company's diversified portfolio. By focusing on agricultural best practices and innovative cultivation techniques, Suresh Balasubramanian enhances the value and productivity of the plantation division. The President's leadership in this specialized area contributes to the overall stability and resource security of the organization.
Raj Vyas - Group President, Corporate & Public Affairs
Raj Vyas, the Group President, Corporate & Public Affairs at Cadila Pharmaceuticals, directs the company's external relations and corporate communications strategy. Vyas manages stakeholder engagement, government relations, and public perception, ensuring a positive and influential corporate image. This leadership position involves shaping public discourse, advocating for industry interests, and fostering strong relationships with government bodies and community organizations. By expertly navigating the corporate and public spheres, Raj Vyas enhances Cadila Pharmaceuticals' brand reputation and supports its mission to provide accessible healthcare solutions. The Group President's strategic communication efforts are vital for building trust and maintaining strong public support for the company's initiatives.
Prabodh Joshi - Group President, Human Resources & Corporate Communications
Prabodh Joshi, the Group President, Human Resources & Corporate Communications at Cadila Pharmaceuticals, leads the company's talent management and internal/external communication strategies. Joshi oversees all human resources functions, including talent acquisition, employee development, and organizational culture, while also directing corporate communications to ensure consistent messaging across all platforms. This dual role is critical for fostering a motivated workforce and maintaining a cohesive brand identity that reflects Cadila Pharmaceuticals' commitment to innovation and quality. By championing employee well-being and driving effective communication, Prabodh Joshi strengthens the organization's internal cohesion and external reputation. The Group President's leadership in HR and communications is fundamental to the company's sustained growth and employee engagement.
Jatin Aggarwal - President, Corporate Communications
Jatin Aggarwal, the President, Corporate Communications at Cadila Pharmaceuticals, drives the company's strategic communication initiatives and public relations efforts. Aggarwal oversees the development and implementation of communication plans designed to enhance brand visibility and stakeholder engagement. This role focuses on managing media relations, crafting key messaging, and ensuring consistent brand representation across all channels, supporting Cadila Pharmaceuticals' mission to deliver accessible healthcare products. By fostering transparent and effective communication, Jatin Aggarwal strengthens the company's public image and reinforces its commitment to quality and innovation. The President's expertise in corporate communications is essential for maintaining a strong and positive corporate narrative.
Ranvir Rana - Head Chief Revenue Officer, Business Development
Ranvir Rana, the Head Chief Revenue Officer, Business Development at Cadila Pharmaceuticals, spearheads revenue generation and strategic market expansion initiatives. Rana directs the development and execution of commercial strategies, identifying new business opportunities and forging key partnerships to drive growth. This leadership position involves overseeing sales, marketing, and business development functions, ensuring alignment with the company's integrated product portfolio, which spans APIs, finished formulations, biotechnology products, and pharmaceutical machinery. By cultivating strong client relationships and exploring emerging markets, Ranvir Rana enhances Cadila Pharmaceuticals' revenue streams and strengthens its global presence. The Chief Revenue Officer's proactive approach to business development is vital for sustained commercial success and market penetration.
Explore Leadership Teams in Manufacturing
ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Companys range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
Company Leadership FJ
Founded in 2008, Ascendis Health is a health and wellness company. They are based in Johannesburg, South Africa.
Company Leadership CN
Pv
DF
LM
Abdi Ibrahim provides pharmaceutical services to the healthcare sector that are beneficial in maintaining people's health. Abdi Ibrahim was founded in 1912 and is based in Istanbul, Turkey.
Company Leadership GO
MÇ
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership TI
CS
SP
MD
Frequently Asked Questions Regarding Cadila Pharmaceuticals Top Executives and Leadership Team
